In mouse models, prophylactic psilocybin prevented or reduced multiple features of chemotherapy-induced peripheral neuropathy ...

Blue Medusa, the new band fronted by former Arch Enemy and The Agonist vocalist Alissa White-Gluz, has dropped its third single, “Crocodile.” Dark, tense and quietly menacing, “Crocodile.” digs into ...

BLUE MEDUSA, the new band led by former ARCH ENEMY and THE AGONIST vocalist Alissa White-Gluz, has released its third single, ...

The FDA’s recent inclusion of certain GLP-1 receptor agonists on a so-called “Green List” is often portrayed as a regulatory milestone aimed at ensuring safer access to these increasingly popular ...

FDA approval positions oral selective OX2R agonism as a first-in-class approach intended to restore orexin signaling and mitigate wake–REM instability underlying narcolepsy type 1 with cataplexy.

As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists. The FDA has approved Takeda’s oveporexton ...

Add Yahoo as a preferred source to see more of our stories on Google. To say Alissa's departure from Arch Enemy was a shock is an understatement. Just a week before, the band had been on a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 2 diabetes receiving acmopatide 4.1 mg ...

Excess weight is a key modifiable risk factor for breast cancer. Glucagon-like peptide-1 receptor agonists (GLP-1) promote weight loss and improve metabolic health, but their effect on breast cancer ...

Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most effective weight loss medication yet. Retatrutide is a triple-agonist ...